Studies related to Insomnia and Ashwagandha

Effect Of Withania Somnifera (Ashwagandha) On The Development Of Chemotherapy-induced Fatigue And Quality Of Life In Breast Cancer Patients

Effect Decrease
Trial Design Cohort
Trial Length n/a
Number of Subjects 100
Gender Female
Age Range 45-64
Body Types Average
Notes for this study:
Supplementation of 2g of the root of ashwagandha thrice daily over six cycles of chemotherapy was able to significantly improve general function and reduce fatigue relative to control.

A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED STUDY OF ASHWAGANDHA ON GENERALIZED ANXIETY DISORDER
Effect Decrease
Values Hamilton’s Anxiety Rating Scale. Mean score. Placebo: before 2.16, after 1.37. Intervention: before 2.25. after 0.51
Trial Design randomized
Trial Length 16months
Number of Subjects 86
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled study, 86 patients with Generalized Anxiety Disorder were assigned to take either placebo or 12 g of ashwagandha sugar granules (unclear dose of ashwagandha and its chemicals) daily for 60 days. The primary and only outcome was the symptoms on the Hamilton Anxiety Rating Scale. Compared with the placebo group, the ashwaganda group saw a statistically significant improvement in "anxious mood" and "tension", while the differences weren't statistically significant for the other symptoms. However, the reduction in every symptom was greater for the ashwagandha group than the placebo group. 58.13% of patients in the ashwagandha group were evaluated as seeing a moderate improvement, 39.53% saw a mild improvement, and 2.32% were unchanged. In the placebo group, this was 0, 81.39, and 18.6%, respectively.

A Standardized Withania Somnifera Extract Significantly Reduces Stress-Related Parameters in Chronically Stressed Humans: A Double-Blind, Randomized, Placebo-Controlled Study
Effect Decrease
Values Hamilton’s Anxiety Rating Scale. Mean score and standard deviation. Placebo: before 2.7 (1.2), after 2.7 (1.1). 125 mg before 3.1 (0.9), after 0.9 (0.8). 250 mg before 3.1 (1.0), after 1.0 (0.8). 500 mg before 3.2 (1.1), after 1.6 (0.7)
Trial Design randomized
Trial Length 16months
Number of Subjects 130
Gender mixed
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, 130 participants with an anxiety disorder were assigned to take 125 mg, 250 mg, or 500 mg of ashwagandha extract containing a minimum of 8% withanolide glycosides, 32% oligosaccharides, and a maximum of 2% withaferin A for 60 days. 32 participants dropped out, with more dropouts in the placebo group. While the placebo group saw no notable changes, the ashwaganda groups all saw statistically significant improvements compared with the placebo group in stress/anxiety, fatigue, flushing, perspiration, loss of appetite, headache and muscle pain, feelings of impending doom, palpitations, dry mouth, sleeplessness, forgetfulness, irritability, and inability to concentrate. The 250 mg and 500 mg groups seemed to be somewhat more potent than the 125 mg group for stress/anxiety, fatigue and inability to concentrate. Serum cortisol, CRP and serum VLDL-C, and blood pressure were statistically significantly reduced compared with placebo in all ashwagandha groups, and DHEAS was significantly increased. Fasting blood glucose, total serum cholesterol, serum triglycerides, LDL-C, and HDL-C were improved in the 250 mg and 500 mg groups compared with placebo, and the 500 mg group was significantly lower than the 125 mg group for all but CRP and fasting blood glucose.
Funding issues for this study:
"We would like to thank Natreon Inc. (New Brunswick, New Jersey) for financial support of this study. " "Dr. Auddy is an employee of Natreon Inc., which is the patent holder of Withania somnifera extract sold under the trade names Essentra® and Sensoril®. Dr. Abedon is an employee of NutraGenesis LLC, which sells Withania somnifera extract exclusively under the trade names Essentra® and Sensoril®. Dr. Ghosal was an unpaid adviser to Natreon Inc. at the time the study was conducted."